Derivation of a subtype-specific biochemical signature of endometrial carcinoma using synchrotron-based Fourier-transform infrared microspectroscopy

Cancer Letters

Volumn 274, Issue 2, 2009, Pages 208-217

  Kelly, Jemma G ^a   Singh, Maneesh N ^a,b   Stringfellow, Helen F ^b   Walsh, Michael J ^a   Nicholson, James M ^c   Bahrami, Fariba ^c   Ashton, Katherine M ^b   Pitt, Mark A ^b   Martin Hirsch, Pierre L ^a,b   Martin, Francis L ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c DARESBURY LABORATORY   (United Kingdom)

Author keywords

sPO2 ; Endometrial carcinoma; FTIR microspectroscopy; Principal component analysis; Synchrotron based radiation; Tamoxifen

Indexed keywords

DNA; PARAFFIN; RNA; TAMOXIFEN;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFRARED SPECTROSCOPY; MIXED MULLERIAN TUMOR; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SYNCHROTRONS; TAMOXIFEN;

EID: 58149289825     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.09.018     Document Type: Article

References (34)

1. Singh M.N., Stringfellow H.F., Paraskevaidis E., Martin-Hirsch P.L., and Martin F.L. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat. Rev. 33 (2007) 91-100 10.1016/j.ctrv.2006.09.008
2. Singh M.N., Stringfellow H.F., Walsh M.J., Ashton K.M., Paraskevaidis E., Abdo K.R., Martin-Hirsch P.L., Phillips D.H., and Martin F.L. Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology 249 (2008) 85-90 10.1016/j.tox.2008.04.009
3. Kaaks R., Lukanova A., and Kurzer M.S. Obesity, endogenous hormones and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomark. Prev. 11 (2002) 1531-1543
4. Hirai M., Hirono M., Oosaki T., Hayashi Y., Yoshihara T., and Matsuzaki O. Prognostic factors relating to survival in uterine endometrioid carcinoma. Int. J. Gynecol. Obstet. 66 (1999) 155-162
5. Grice J., Ek M., Greer B., Koh W.J., Muntz H.G., Cain J., Tamimi H., Stelzer K., Figge D., and Goff B.A. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol. Oncol. 69 (1998) 69-73
6. Sahdev A. Imaging the endometrium in postmenopausal bleeding. BMJ 334 (2007) 635-636
7. Beresford S.A., Weiss N.S., Voigt L.F., and McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 (1997) 458-461
8. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP). J. Natl. Cancer Inst. 86 (1994) 527-537
9. Shepherd J.H. Revised FIGO staging for gynaecological cancer. BJOG 96 (1989) 889-892
10. Frei K.A., and Kinkel K. Staging endometrial cancer: role of magnetic resonance imaging. J. Magn. Reson. Imaging 13 (2001) 850-855
11. Key T.J., and Pike M.C. The dose effect relationship between "unopposed" oestrogens and endometrial mitotic state: its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer 57 (1988) 205-212
12. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Bergström R., Lindgren A., Correia N., and Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst. 91 (1999) 1131-1137
13. Floren L.C., Hebert M.F., Venook A.P., Jordan V.C., Cisneros A., and Somberg K.A. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann. Oncol. 9 (1998) 1123-1126
14. Phillips D.H. Understanding the genotoxicity of tamoxifen?. Carcinogenesis 22 (2001) 839-849
15. Bergman L., Beelen M.L.R., Gallee M.P.W., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356 (2000) 881-887
16. Van Leeuwen F.E., Benraadt J., Coebergh J.W., Kiemeney L.A., Gimbrere C.H., Otter R., Schouten L.J., Damhuis R.A., Bontenbal M., Diepenhorst F.W., et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452
17. Oktay K., Buyuk E., Davis O., Yermakova I., Veeck L., and Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum. Reprod. 18 (2003) 90-95
18. Han X., and Liehr J.G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52 (1992) 1360-1363
19. Osborne M.R., Hewer A., Hardcastle I.R., Carmichael P.L., and Phillips D.H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56 (1996) 66-71
20. Tannenbaum S.R. Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin. Oncol. 24 (1997) S1-6-8
21. Williams G.M., Iatropoulos M.J., Djordjevic M.V., and Kaltenberg O.P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14 (1993) 315-317
22. Greaves P., Goonetilleke R., Nunn G., Topham J., and Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53 (1993) 3919-3924
23. Beland F.A., Churchwell M.I., Doerge D.R., Parkin D.R., Malejka-Giganti D., Hewer A., Phillips D.H., Carmichael P.L., Gamboa da Costa G., and Marques M.M. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J. Natl. Cancer Inst. 96 (2004) 1099-1104
24. Walsh M.J., German M.J., Singh M., Pollock H.M., Hammiche A., Kyrgiou M., Stringfellow H.F., Paraskevaidis E., Martin-Hirsch P.L., and Martin F.L. IR microspectroscopy: potential applications in cervical cancer screening. Cancer Lett. 246 (2007) 1-11 10.1016/j.canlet.2006.03.019
25. German M.J., Hammiche A., Ragavan N., Tobin M.J., Cooper L.J., Matanhelia S.S., Hindley A.C., Nicholson C.M., Fullwood N.J., Pollock H.M., and Martin F.L. Infrared spectroscopy with multivariate analysis potentially facilitates the segregation of different types of prostate cell. Biophys. J. 90 (2006) 3783-3795 10.1529/biophysj.105.077255
26. German M.J., Pollock H.M., Zhao B., Tobin M.J., Hammiche A., Bentley A., Cooper L.J., Martin F.L., and Fullwood N.J. Characterization of putative stem cell populations in the cornea using synchrotron infrared microspectroscopy. Inv. Ophthal. Vis. Sci. 47 (2006) 2417-2421 10.1167/iovs.05-1254
27. - modifications as a marker of the putative stem cell region of human intestinal crypts. Stem Cells 26 (2008) 108-118 10.1634/stemcells.2007-0196
28. Walsh M.J., Singh M.N., Stringfellow H.F., Pollock H.M., Hammiche A., Grude O., Fullwood N.J., Pitt M.A., Martin-Hirsch P.L., and Martin F.L. FTIR microspectroscopy coupled with two-class discrimination segregates markers responsible for inter- and intra-category variance in exfoliative cervical cytology. Biomark. Insights 3 (2008) 179-189
29. Martin F.L., German M.J., Wit E., Fearn T., Ragavan N., and Pollock H.M. Identifying variables responsible for clustering in discriminant analysis of data from infrared microspectroscopy of a biological sample. J. Comput. Biol. 14 (2007) 1176-1184
30. Malins D.C., Johnson P.M., Barker E.A., Polissar N.L., Wheeler T.M., and Anderson K.M. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc. Natl. Acad. Sci. USA 100 (2003) 5401-5406
31. Gazi E., Dwyer J., Lockyer N., Gardner P., Vickerman J.C., Miyan J., Hart C.A., brown M., Shanks J.H., and Clarke N. The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer. Faraday Discuss. 126 (2004) 41-59
32. Argov S., Sahu R.K., Bernshtain E., Salman A., Shohat G., Zelig U., and Mordechai S. Inflamatory bowel diseases as an intermediate stage between normal and cancer: a FTIR-microspectroscopy approach. Biopolymers 75 (2004) 384-392
33. Yang Y., Sulé-Suso J., Sockalingum G.D., Kegelaer G., Manfait M., and El Haj A.J. Study of tumor cell invasion by Fourier transform infrared microspectroscopy. Biopolymers 78 (2005) 311-317
34. Maxwell G.L., Risinger J.I., Hayes K.A., Alvarez A.A., Dodge R.K., Barrett J.C., and Berchuck A. Racial disparity in the frequency of PTEN mutations but not microsatellite instability in advanced endometrial cancers. Clin. Cancer Res. 6 (2000) 2999-3005